Predicting Tolerance to Anthracycline Chemotherapy Using Electrocardiogram-Based Artificial Intelligence in Sarcoma.

ABSTRACT:

Objective

The objective of this study was to understand the utility of artificial intelligence-enabled electrocardiogram (AI-ECG) to assess the tolerability of anthracycline chemotherapy.

Patients and methods

From December 18, 2006 to October 15, 2020, we identified adults with sarcoma who were treated with anthracycline chemotherapy at our institution who had an ECG within 1 year prior to treatment initiation. Utilizing previously defined AI-ECG nomograms, we obtained age and ejection fraction (EF) predictions. Changes in AI-ECG age were correlated with chemotherapy tolerance (the rates of dose reductions, treatment delays, and early discontinuation). We measured the sensitivity and specificity of the ECG to predict an EF of less than 50% or 35% prior to treatment and compa

SUBMITTER: Korleski JB 

PROVIDER: S-EPMC12309600 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature